Clinical trial
Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence &…
NCT00327184 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00327184 |
|---|---|
| Title | Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine |
| Official title | Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC Given With Infanrix™ Penta Versus NeisVac-C™ Given With Infanrix™ Hexa at 3, 5 Months of Age and Persistence Prior to a Hib-MenC Booster at 11 Months and Immunogenicity of the Booster |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neisseria Meningitidis, Haemophilus Influenzae Type b |
| Intervention type | Biological |
| Interventions | Haemophilus influenzae type b- and meningococcal serogroup C (vaccine), Infanrix Penta, Infanrix hexa, Neis-Vac-C |
| Enrollment | 709 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | May 18, 2006 |
| Last update posted | Oct 7, 2016 |
| Countries | Finland, Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: